phrykt

Amneal Pharmaceuticals, Inc. (AMRX): who owns it and who trades it

As of Nov 16, 2026, AMRX insiders reported 6 open-market sales worth $8.3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason B. Daly (Vice president), with $3.8M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Amneal Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AMRX

305 funds and institutions reported AMRX shares worth $2.9B at the end of Q2 2026, about 53% of the company. The largest holder is BlackRock, Inc. with 8.3%.

Funds and institutions (13F) 53%Everyone else 47%

10 largest owners, by share of the company

BlackRock, Inc.8.3%
Tpg Gp A, LLC3.9%
Vanguard Portfolio Management LLC3.8%
Rubric Capital Management LP3.2%
Vanguard Capital Management LLC2.4%
State Street Corp2.3%
Dimensional Fund Advisors LP1.8%
Geode Capital Management, LLC1.6%
Assenagon Asset Management S.A.1.5%
Nantahala Capital Management, LLC1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.26.56M8.33%$460M+8%
Tpg Gp A, LLC12.33M3.86%$213MNo change
Vanguard Portfolio Management LLC12.14M3.80%$210M+7%
Rubric Capital Management LP10.17M3.19%$176M-8%
Vanguard Capital Management LLC7.71M2.42%$133M+2%
State Street Corp7.36M2.31%$127M+8%
Dimensional Fund Advisors LP5.79M1.82%$100M+2%
Geode Capital Management, LLC5.14M1.61%$89M+13%
Assenagon Asset Management S.A.4.89M1.53%$84.7M+59%
Nantahala Capital Management, LLC4.54M1.42%$78.5M+60%
Morgan Stanley4.11M1.29%$71.1M-11%
Neuberger Berman Group LLC3.89M1.22%$67.3M+6%
Invesco Ltd.3.50M1.10%$60.6M+10%
Nuveen, LLC3.32M1.04%$57.6M+3%
Allspring Global Investments Holdings, LLC3.30M1.03%$55.9M+29%
Goldman Sachs Group Inc3.01M0.94%$52.2M+5%
Charles Schwab Investment Management Inc2.15M0.67%$37.2M-2%
Sixth Street Partners Management Company, L.P.2.15M0.67%$37.2M–
Northern Trust Corp1.91M0.60%$33.1M+12%
Acadian Asset Management LLC1.65M0.52%$28.6M-15%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AMRX insiders reported $0 of open-market purchases and $8.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$8.3M
6 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 13, 2026
Filed Aug 14, 2026

Purchases and sales by month

$7.2M$7.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 13, 2026John KielyDirectorSale50,000$17.64$882KForm 4
Aug 12, 2026Nikita ShahVice presidentSale146,403$17.51$2.6MForm 4
Aug 12, 2026Jason B. DalyVice presidentSale210,000$17.40$3.7MForm 4
Aug 11, 2026Jason B. DalyVice presidentSale6,613$17.70$117KForm 4
May 11, 2026Deborah M. AutorDirectorSale34,819$12.94$451KForm 4
Nov 17, 2025Ted C NarkDirectorSale50,000$11.72$586KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jason B. DalyEVP, Chief Legal Officer–$3.8MAug 12, 2026
Nikita ShahExecutive Vice President–$2.6MAug 12, 2026
John KielyDirector–$882KAug 13, 2026
Ted C NarkDirector–$586KNov 17, 2025
Deborah M. AutorDirector–$451KMay 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AMRX short interest

Low short interest. 3.3% of AMRX shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went up 43%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.39M AMRX shares were sold short, 3.3% of the shares outstanding, down 19.0% from the report before. At the average daily volume of 4.09M shares, buying them all back would take about 2.8 trading days (days to cover).

Shares short, % of all shares

3.27%May 15Oct 304.71%

Days to cover

2.8May 15Oct 308.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.39M3.27%-19%4.09M2.8
Oct 15, 202614.07M4.41%+25%3.81M3.7
Sep 30, 202611.28M3.53%-0%3.69M3.1
Sep 15, 202611.29M3.54%+7%1.70M6.6
Aug 31, 202610.57M3.31%+11%1.43M7.4
Aug 14, 20269.51M2.98%+14%1.95M4.9
Jul 31, 20268.32M2.61%+2%1.82M4.6
Jul 15, 20268.12M2.54%+4%1.80M4.5
Jun 30, 20267.84M2.46%-1%2.71M2.9
Jun 15, 20267.92M2.48%+5%2.04M3.9
May 29, 20267.53M2.36%-5%1.62M4.6
May 15, 20267.96M2.50%-31%1.48M5.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Amneal Pharmaceuticals company events

Amneal Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 10, 2026DealThe information set forth in the Introductory Note of this Report is incorporated into this Item 2.01 by reference. Filing
  3. Aug 3, 2026AgreementAmneal Pharmaceuticals, Inc.’s subsidiary, Amneal Pharmaceuticals LLC, and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 3 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto… Filing
  4. Jul 31, 2026VoteReported shareholder vote results. Filing
  5. Jul 30, 2026ResultsReleased financial results. Filing
  6. May 7, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 22, 2026AgreementAmneal Pharmaceuticals, Inc., a Delaware corporation, entered into a Membership Interest Purchase Agreement with Kashiv BioSciences, LLC, KB Seller Representative, LLC and the equityholders of Kashiv named therein, pursuant to which, among other matters and on the terms and subject to the… Filing
  9. Feb 27, 2026ResultsReleased financial results. Filing
  10. Feb 3, 2026AgreementAmneal Pharmaceuticals, Inc.’s subsidiary, Amneal Pharmaceuticals LLC, and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto… Filing
  11. Jan 28, 2026AnnouncementAmneal Pharmaceuticals, Inc. determined that it will make effective its nationwide agreement to settle a substantial majority of the opioids-related claims brought against the Company by various states and subdivisions, having previously secured sufficient participation by those states and… Filing
  12. Jan 13, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Amneal Pharmaceuticals financials

Famous investors that hold AMRX

2 of the 50 well-known investors we track reported holding AMRX in their latest 13F filing. The largest position is Ken Griffin's, worth $141M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20266.99M$141M0.1%+525%
Israel Englander · Millennium ManagementQ3 2026294,727$5.9M0.0%+1897%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Amneal Pharmaceuticals, Inc. (AMRX) stock

Who owns the most AMRX stock?

The largest reported owner of Amneal Pharmaceuticals, Inc. (AMRX) is BlackRock, Inc., with 8.3% of the company. In total, 305 funds and institutions reported holding AMRX at the end of Q2 2026, together about 53% of the shares. See the largest owners.

Are AMRX insiders buying or selling?

In the last 12 months, AMRX insiders reported no open-market purchases and 6 sales worth $8.3M. The latest trade was on Aug 13, 2026. See every trade.

What is the short interest in AMRX?

As of Oct 30, 2026, 11.39M AMRX shares were sold short, 3.3% of the shares outstanding, down 19.0% from the report before. At the average daily volume of 4.09M shares, buying them all back would take about 2.8 trading days (days to cover). See the history.

Which famous investors hold AMRX?

2 of the 50 well-known investors we track reported AMRX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $141M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.